NICE plans to lift a restriction on 3 Alzheimer's drugs

10/6/2010 | Reuters

The U.K. National Institute for Health and Clinical Excellence issued a draft guidance that would reverse a 2006 decision to restrict patient access to certain Alzheimer's disease drugs. The agency recommended that Eisai and Pfizer's Aricept, Novartis' Exelon and Shire's Reminyl be covered by the National Health Service for patients with mild and moderate Alzheimer's.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID